Replacement therapy for Addison's disease: Recent developments

Expert Opinion on Investigational Drugs

Volumn 17, Issue 4, 2008, Pages 497-509

  Løvås, Kristian ^a,b   Husebye, Eystein S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Addison's disease; Adrenal insufficiency; Replacement therapy

Indexed keywords

ALDOSTERONE; ANDROGEN; CHRONOCORT; CORTICOTROPIN; CORTISONE ACETATE; CORTODOXONE; DEXAMETHASONE; DUOCORT; EPLERENONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; INFLUENZA VACCINE; MINERALOCORTICOID; PLACEBO; PNEUMOCOCCUS VACCINE; PRASTERONE; PRASTERONE SULFATE; PREDNISOLONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SPIRONOLACTONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADDISON DISEASE; ADRENAL INSUFFICIENCY; CLINICAL TRIAL; CONTINUOUS INFUSION; CUSHINGOID SYNDROME; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG RELEASE; DRUG SYNTHESIS; EVENING DOSAGE; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; INFLUENZA; LABOR; LONG TERM CARE; MORNING DOSAGE; MORTALITY; PLASMA RENIN ACTIVITY; PREGNANCY; QUALITY OF LIFE; REVIEW; SELF REPORT; STREPTOCOCCUS INFECTION; BLOOD; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM; TREATMENT OUTCOME;

ADDISON DISEASE; ANDROGENS; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; MINERALOCORTICOIDS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 42149131453     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.4.497     Document Type: Review

References (139)

1. Løvås K, Husebye ES. Addison's disease. Lancet 2005;365(9476):2058-61
2. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003;361(9372):1881-93
3. Orth DN, Kovacs WJ. The adrenal cortex. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW, editors. Philadelphia: W.B. Saunders; 1998. p. 517-664
4. Løvås K, Husebye ES. High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf). 2002;56(6):787-91
5. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004;350(20):2068-79
6. Mathis D, Benoist C. A decade of AIRE. Nat Rev Immunol 2007;7(8):645-50
7. Myhre AG, Undlien DE, Løvås K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002;87(2):618-23
8. Blomhoff A, Lie BA. Myhre AG, et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J Clin Endocrinol Metab 2004;89(7):3474-6
9. Skinningsrud B, Husebye ES, Gervin K, et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur J Hum Genet 2008. Epub Feb 27
10. Gambelunghe G, Falorni A, Ghaderi M, et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J Clin Endocrinol Metab 1999;84(10):3701-7
11. Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf) 2002; 56(5):581-8
12. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional Analysis. J Clin Endocrinol Metab 2007;92:3912-22
13. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in Primary Adrenal Insufficiency: a randomised, controlled trial. J Clin Endocrinol Metab 2008;93:400-9
14. al-Shoumer KA, Cox KH, Hughes CL, et al. Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy. J Clin Endocrinol Metab 1997;82(8):2653-9
15. Zelissen PMJ. Addison Patients in the Netherlands. English edition. The Hague: Dutch Addison Society; 1994
16. Braatvedt GD, Joyce M, Evans M, et al. Bone mineral density in patients with treated Addison's disease. Osteoporos Int 1999;10(6):435-40
17. Jodar E, Valdepenas MP, Martinez G, et al. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol (Oxf) 2003;58(5):617-20
18. Valero MA, Leon M, Ruiz Valdepenas MP, et al. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner 1994;26(1):9-17
19. Lukert BP. Editorial: glucocorticoid replacement - how much is enough? J Clin Endocrinol Metab 2006;91(3):793-4
20. Bergthorsdotti R, Leonsson-Zachrisson M, Oden A, et al. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006;91(12):4849-53
21. Tomlinson JW, Holden N, Hills RK, et al. Association between Premature mortality and hypopituitarism West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357(9254):425-31
22. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, et al. Hypopituitarism. Lancet 2007;369(9571):1461-70
23. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71
24. Dickstein G. On the term "relative adrenal insufficiency" - or what do we really measure with adrenal stimulation tests? J Clin Endocrinol Metab 2005;90(8):4973-4
25. Veldhuis JD, Pincus SM. Orderliness of hormone release patterns: a complementary measure to conventional pulsitile and circadian analyses. Eur J Endocrinol 1998;138(4):358-62
26. Bornstein SR, Breidert M, Ehrhart-Bornstein M, et al. Plasma catecholamines in patients with Addison's disease. Clin Endocrinol (Oxf) 1995;42(2):215-18
27. Stewart PM. Adrenal replacement therapy: time for an inward look to the medulla? J Clin Endocrinol Metab 2004,89(8):3677-8
28. Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest. J Appl. Physiol 2004;96(4):1406-14
29. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242(4878):583-5
30. Diederich S, Eigendorff E, Burkhardt P, et al. 11 beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002;87(12);5695-701
31. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005;186(1):1-20
32. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 2066;147(12):5564-7
33. Cohen N, Gilbert R, Wirth A, et al. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. J Clin Endocrinol Metab 1996;81(4):1411-5
34. Smith SJ, MacGregor GA, Markandu ND, et al. Evidence that patients with Addisons disease are undertreated with fludrocortisone. Lancet 1984;1(8367):11-4
35. Jadoul M, Ferrant A, De Plaen JF, et al. Mineralocorticoids in the management of primary adrenocortical insufficiency. J Endocrinol Invest 1991;14(2):87-91
36. Jeffcoate W. Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann Clin Biochem 1999;36(Pt 2):151-7
37. Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticorropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992;75(1):259-64
38. Flad TM, Conway JD, Cunningham SK, et al. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf) 1996;45(5):529-34
39. Thompson DG, Mason AS, Goodwin FJ. Mineralocorticoid replacement in Addison's disease. Clin Endocrinol (Oxf) 1979;10(5):499-506
40. de Kloet ER, Karst H, Joels M. Corticosteroid hormones in the central stress response: Quick-and-slow. Front Neuroendocrinol. Epub 2007 Oct 24
41. Kerrigan JR, Veldhuis JD, Leyo SA, et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993;76(6):1505-10
42. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991;72(1):39-45
43. Veldhuis JD, Iranmanesh A, Johnson ML, et al. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 1990;71(2):452-63
44. Kenny FM, Preeyasombat C, Migeon CJ. Cortisol production rate. II. Normal infants, children, and adults. Pediatrics 1966;37(1):34-42
45. Kraan GP, Dullaart RP, Pratt JJ, et al, The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab 1998;83(4):1247-52
46. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11 beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25(5):831-66
47. Crown A, Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 2005;63(5):483-92
48. Rhen T, Cidlowski JA. Antiinflammatory action of glucocdrticoids - new mechanisms for old drugs. N Engl J Med 2005;353(16):1711-23
49. Tasker JG, Di S, Malcher-Lopes R. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology 2006;147(12):5549-56
50. Pratt WB, Galigniana MD, Harrell JM, et al. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 2004;16(8):857-72
51. Vermeer H, Hendriks-Stegeman BI, Verrijn Stuart AA, et al. A comparison of in vitro bioassays to determine cellular glucocorticoid sensitivity. Eur J Endocrinol 2004;150(1):41-7
52. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997;46(3):255-61
53. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 1997;46(3):263-8
54. Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2004;61(3):367-75
55. Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Invest 2003;26(11):1071-5
56. Barbetta L, Dall'Asta C, Re T, et al. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Invest 2005;28(7):652-7
57. Wichers M, Springer W, Bidlingmaier F, et al. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin Endocrinol (Oxf) 1999;50(6):759-65
58. Riedel M, Wiese A, Schurmeyer TH, et al. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp Clin Endocrinol 1993;101(2):106-11
59. Nordenström A, Marcus C, Axelson M, et al. Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity. J Clin Endocrinol Metab 1999;84(4):1210-3
60. Fariss BL, Hane S, Shinsako J, et al. Comparison of absorption of cortisone acetate and hydrocartisone hemisuccinate. J Clin Endocrinol Metab 1978;47(5):113-40
61. Filipsson H, Monson JP, Koltowska-Haggstrom M, et al. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006;91(10):3954-61
62. Suliman AM, Freaney R, Smith TP, et al. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2003;59(3):380-7
63. Newell-Price J, Whiteman M, Rostami-Hodjegan A, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008;68(1):130-5
64. Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007;157(1):109-12
65. Johannsson G, Bergthorsdottir R, Nilsson A, et al. Improved glucocorticoid replacement therapy by a novel oral hydrocortisone modified-release tablet [poster]. The Endocrine Society's 89th Annual Meeting, ENDO, Toronto; 2007:4-12
66. Thomson AH, Devers MC, Freel M, et al. Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral Administration to patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2007;66(6):789-96
67. Kraan GP, Dullaart RP, Pratt JJ, et al. Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. J Steroid Biochem Mol Biol 1997;63(1-3):139-46
68. Bright GM. Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J Clin Endocrinol Metab 1995;80(3):770-5
69. Fukushima DK, Bradlow HL, Hellman L, et al. Metabolic transformation of hydrocortisone-4-C14 in normal men. J Biol Chem 1960;235:2246-52
70. Charbonneau. A, Luu-The V. Assignment of steroid 5beta-reductase (SRD5B1) and its pseudogene (SRD5BP1) to human chromosome bands 7q32→q33 and 1q23→q25, respectively, by in situ hybridization. Cytogenet Cell Genet 1999;84(1-2):105-6
71. Hierholzer K, Bühler H. Metabolism of cortical steroid hormones and their general mode of action. In: Comprehensive Human Physiology. Greger R, Windhorst U, editors. From cellular mechanism to integration. Berlin: Springer-Verlag; 1996. p. 403-29
72. Morris DJ, Latif SA, Hardy, MP, et al. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol 2007;104(3-5):161-8
73. Cooper H, Bhartacharya B, Verma V, et al. Liquotice and soy sauce, a life-saving concoction in a patient with Addison's disease. Ann Clin Biochem 2007;44(Pt 4):397-9
74. Purnell JQ, Brandon DD, Isabelle LM, et al. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 2004;89(1):281-7
75. Valsamakis G; Anwar A, Tomlinson JW, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89(9):4755-61
76. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003;88(10):4924-31
77. Voccia E, Saenger P, Peterson RE, et al. 6 beta-Hydroxycortisol excretion in hypercortisolemic states. J Clin Endocrinol Metab 1979;48(3):467-71
78. Karssen AM, Meijer OC, van der Sandt IC, et al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 2001;142(6):2686.94
79. Marzolini C, Paus E, Budin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75(1):13-33
80. Xie W, Uppal H, Saini SP, et al. Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. Drug Discov Today 2004;9(10):442-9
81. Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73(1):41-50
82. Wentworth JM, Agostini M, Love J, et al. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166(3):R11-16
83. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1(4):259-66
84. Konishi H, Tanaka K, Minouchi T, et al. Urinary 6beta-hydroxycortisol 17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction. Ann Clin Biochem 2004;41(Pt 4):335-7
85. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003;59(10):713-33
86. Horsmans Y, Desager JP, Harvengt C. Absence of CYP3A genetic polymorphism. assessed by urinary excretion of 6 beta-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992;71(4):258-61
87. Wong V, Yan T, Donald A, et al. Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clin Endocrinol (Oxf) 2004;61(1):131-7
88. Løvås K, Thorsen TE, Husebye ES. Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison's disease. J Endocrinol Invest 2006; 29(8):727-31
89. Hangaard J, Andersen M, Grodum E, et al. Pulsatile luteinizing hormone secretion in patients with Addison's disease. Impact of glucocorticoid substitution. J Clin Endocrinol Metab 1998;83(3):736-43
90. Hangaard J, Andersen M, Grodum E, et al. The effects of endogenous opioids and cortisol on thyrotropin and prolactin secretion in patients with Addison's disease. J Clin Endocrinol Metab 1999;84(5):1595-601
91. Lever EG, McKerron CG. Auto-immune Addison's disease associated with hyperprolactinaemia. Clin Endocrinol (Oxf) 1984;21(4):451-7
92. Al-Shoumer KA, Ali K, Anyaoku V, et al. Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism. Clin Endocrinol (Oxf) 1996;45(2):171-8
93. Arlt W, Rosenthal C, Hahner S, et al. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 2006;64(4):384-9
94. Løvås K, Curran S, Husebye ES, et al. Development of an Addison's disease-specific questionnaire (ADDIQoL) [Poster]. The Endocrine Society's 89th Annual Meeting; ENDO, Toronto; 2007;abstract P4-17
95. Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986;15(2):213-28
96. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;81(9):3147-51
97. Vermeulen A, Deslypere JP, Schelfhout W, et al. Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab 1982;54(1):187-91
98. Orentreich N, Brind JL, Vogelman JH, et al. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992;75(4):1002-4
99. Berr C, Lafont S, Debuire B, et al. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci USA 1996;93(23):13410-5
100. Moffat SD, Zonderman AB, Harman SM, et al. The relationship between longitudinal declines in dehydroepiandrosterone sulfate concentrations and cognitive performance in older men. Arch Intern Med 2000;160(14):2193-8
101. Rannevik G, Carlström K, Jeppsson S, et al. A prospective long-term study in women from pre-menopause to post-menopause: changing profiles of gonadotrophins, oestrogens and androgens. Maturitas 1986;8(4):297-307
102. Nafziger AN, Bowlin SJ, Jenkins PL, et al. Longitudinal changes in dehydroepiandrosterone concentrations in men and women. J Lab Clin Med 1998;131(4):316-23
103. Mazat L, Lafont S, Berr C, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA 2001;98(14):8145-50
104. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24(2):152-82
105. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993;169(6):1536-9
106. Coles AJ, Thompson S, Cox AL, et al. Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. Eur J Immunol 2005;35(12):3694-703
107. Mellon SH, Griffin LD. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002;13(1):35-43
108. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 1999;140(8):3843-52
109. Majewska MD. Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Ann NY Acad Sci 1995;774:111-20
110. Kimonides VG, Spillantini MG, Sofroniew MV, et al. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 1999;89(2):429-36
111. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355(16):1647-59
112. Grimley Evans J, Malouf R, Huppert F, et al. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 2006;(4):CD006221
113. Shiften JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343(10):682-8
114. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82(10):3498-505
115. Villareal DT. Effeccs of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol 2002;1(6):349-57
116. Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001;86(10):4686-92
117. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 2001;145(4):457-61
118. Yen SS. Dehydroepiandrosterone sulfate and longevity: new clues for an old friend. Proc Natl Acad Sci USA 2001;98(15):8167-9
119. Christiansen JJ, Andersen NH, Sörensen KE, et al. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol (Oxf) 2007;66(3):426-33
120. Gebre-Medhin G, Husebye ES, Mallmin H, et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol (Oxf) 2000;52(6):775-80
121. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005;54(3):765-9
122. Bilger M, Speraw S, LaFranchi SH, et al. Androgen replacement in adolescents and young women with hypopituitarism. J Pediatr Endocrinol Metab 2005;18(4):355-62
123. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterene for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression, J Clin Endocrinol Metab 1998;83(6):1928-34
124. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;34(14):1013-20
125. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocritiol Metab 2000;85(12):4650-6
126. Johannsson G, Burman P, Wiren L, et al. Low dose dehydroepiandrosterone a affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002;87(5):2046-52
127. Løvås K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003;88(3):1112-8
128. Miller KK, Biller BM, Schaub A, et al. Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab 2007;92(7):2474-9
129. Miller KK, Biller BM, Beauregard C, et al. Effects of restosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2006;91(5):1683-90
130. Labrie F, Belanger A, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82(8):2403-9
131. Luger A, Deuster PA, Kyle SB, et al. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N Engl J Med 1987;316(21):1309-15
132. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N Engl J Med 1988;319(6):348-53
133. Smith R, Mesanio S, Nicholson R, et al. The regulation of human parturition. In: Birth, Distress and Disease. Power ML, Schulkin J, editors. Cambridge: Cambridge University Press; 2005. p. 74-87
134. Seckl JR, Drake AJ, Holmes MC. Prenatal glucocorticoids and the programming of adult disease. In: Birth, Distress and Disease. Power ML, Schulkin J, editors. Cambridge: Cambridge University Press; 2005. p. 142-82
135. Molsa M, Heikkinen T, Hakkola J, et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 2005;78(2):123-31
136. Fagundes VG, Lamas CC, Francischetti EA. Renin-angiotensin-aldosterone system in normal and hypertensive pregnancy. Response to postural stimuli. Hypertension 1992;19(2 Suppl):II74-8
137. Osler M. Addison's disease and pregnancy. Acta Endocrinol (Copenh) 1962;41:67-78
138. Albert E, Dalaker K, Jorde R, et al. Addison's disease and pregnancy. Acta Obstet Gynecol Scand 1989;68(2):185-7
139. Agha A, Liew A, Finucane F, et al. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency. Clin Endocrinol (Oxf) 2004;60(6):688-93